di-leu16-il2
Recombinant proteinexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00720135)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Intraocular Lymphoma · Phase 1
- Lymphoma · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large-Cell, Anaplastic · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Lymphomatoid Granulomatosis · Phase 1
- Testicular Neoplasms · Phase 1
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- B-lymphocyte antigen CD20Immunity, passive
MS4A1 immunity, passive
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- IL2
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650391 ↗
Also known as
- di-leu16-il2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02151903 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2014 | Alopexx |
| NCT01874288 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2013 | Alopexx |
| NCT00720135 | Phase 1 | Jan 1, 2008 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alopexx | For profit | 2 | 2 | 1 | 2013 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2008 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2008 |
3 organizations
Page 1 / 1